TheStreet.com  8 hrs ago  Comment 
PHILADELPHIA (TheStreet) -- Treatment with the cancer immunotherapy known as chimeric antigen receptor T cells, or CAR-T, was found to be relatively safe and feasible in an early-stage study involving a small number of patients with advanced solid...
Motley Fool  Apr 16  Comment 
The FDA has approved Novartis and Momenta Pharmaceuticals, Inc.'s biosimilar to Teva Pharmaceuticals Copaxone.
Wall Street Journal  Apr 16  Comment 
The FDA approved the first generic version of Teva’s blockbuster multiple-sclerosis drug Copaxone, which was developed by Novartis’s Sandoz business and Momenta, but it is unclear when it may come to market.
FiercePharma  Apr 15  Comment 
Novartis already has some positive data for Arzerra, a chronic lymphocytic leukemia (CLL) drug it picked up in its $16 billion buyout of GlaxoSmithKline's cancer drugs. Given the competition in the category, Novartis can use whatever boost it can...
FierceBiotech  Apr 9  Comment 
A Dutch immuno-oncology player that has received venture funding from Johnson & Johnson, Novartis and Pfizer is preparing to list on Nasdaq. The company--Merus--hopes to raise upward of €100 million ($107 million) to advance its pipeline of...
FiercePharma  Apr 7  Comment 
Drugs that treat brain-related diseases are often tied to troubling side effects. Now an analysis of FDA side-effects reports by healthcare informatics firm AdverseEvents has uncovered more potential safety problems for the meds.
FiercePharma  Apr 6  Comment 
Which Big Pharma companies have the biggest market caps in the industry? The Motley Fool has a breakdown of the top 10, but we'll give you a hint: The list begins with Johnson & Johnson and Novartis.
Wall Street Journal  Apr 6  Comment 
Juno Therapeutics said Monday that it settled a patent dispute with Novartis Pharmaceuticals.
FiercePharma  Apr 2  Comment 
Did Novartis and Roche campaign against study data supporting cheap Avastin eye injections as a substitute for their own purpose-made vision drug Lucentis? The BMJ says they did, aiming to "undermine and divert attention" from trials...
FierceBiotech  Apr 2  Comment 
Pharma heavyweight Novartis has stepped in to help bankroll Berkeley, CA-based Caribou Biosciences, one of the upstart leaders in the race to develop the cutting-edge CRISPR-Cas9 gene editing technology.


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki